Fig. 4From: Neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy for human epidermal growth factor receptor 2 positive breast cancer: a real-world retrospective single-institutional study in ChinaQualitative changes of IHC indicators. A Changes of ER status. B Changes of PR status. C Changes of Ki-67 levelsBack to article page